AstraZeneca to develop oncology drug using SPL’s DEP™ technology
Starpharma today announced the signing of an extension to the existing collaboration agreement with AstraZeneca to commence scale up of a dendrimer enhanced oncology molecule (“DEP™ conjugate”) for further development.
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2015.
DEP™ Docetaxel Trial Dose Exceeds Common Taxotere® Dose Level
Starpharma today released an update to the progress of its phase 1 clinical trial of DEP™ docetaxel for advanced solid cancers. The DEP™ docetaxel dose level now exceeds the most commonly used dose for Taxotere® of 75mg/m2, with no dose limiting toxicities (DLT), including neutropenia, having been observed to date.
Herald Sun: Star turn for Carlton and United Breweries
The Herald Sun's Paul Glider reports that "beer and biotechnology does not sound like a recipe for success but it's a match made in hoppy heaven for the research team at Starpharma".
Channel 9 News: Starpharma’s DEP™ docetaxel drug
The benefits of Starpharma’s DEP™ docetaxel drug which is currently in clinical trials, has been featured nationally on Channel 9 News.
Shareholder Update March 2015
In this Issue:
› Phase 1 DEP™ docetaxel clinical trial update
› DEP™ docetaxel in the news
› Partner news
› Starpharma targeting key growth areas in Oncology
› Bacterial vaginosis: Prevention of recurrence/Symptomatic relief
› VivaGel® condom
› Corporate news
› Starpharma half yearly financial results
Download: Shareholder Update March 2015 (pdf file, 1MB)
Starpharma to present at March US investor conferences
Starpharma today announced that Chief Executive Officer, Dr Jackie Fairley will present at both the leading ROTH Conference in California and the ASX Spotlight conference in New York in the coming week.
Starpharma presents at ASX Investor Series
Starpharma is presenting to more than 200 investors at ASX Investor Series event in Sydney.
The ASX Investor Series is hosted by the ASX in conjunction with Finance News Network (FNN) and is designed to engage the investment community and bring together ASX-listed companies, investors and financial market participants.
Interim Report and Half-Year Financial Results
Starpharma today released its interim report and financial results for the half-year ended 31 December 2014.
Financial Summary
- Reported loss of $8.5M (Dec 2013: $5.6M)
- Cash position at 31 December 2014 of $39.3M
- R&D tax incentives of $1.6M reported in the half-year (Dec 2013: $2.6M)
- Receipt of $4.2M R&D tax incentive refund
- $20.5M net proceeds from equity placement and share purchase plan
Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2014.